Skip to main content
Premium Trial:

Request an Annual Quote

James Gibson, Dennis Brown, Xandra Breakefield, Richard Edelson, Francis Collins

James Gibson has resigned his position as Affymetrix’s VP and principal accounting officer. Gibson is leaving his post at Affy in order to pursue a senior financial management job at another company, Affy said in a filing with the US Securities and Exchange Commission.

Exosome Diagnostics has added three new members to its scientific advisory board: Dennis Brown, Xandra Breakefield, and Richard Edelson.
Brown is director of Massachusetts General Hospital’s program in membrane biology and a professor at Harvard Medical School. Breakefield is a geneticist at Mass General and a professor of neurology at Harvard Medical School. Edelson is director of the Yale Cancer Center and a professor at Yale University School of Medicine.

Former National Human Genome Research Institute Director Francis Collins has been named winner of the Inamori Ethics Prize from the Inamori International Center for Ethics and Excellence at Case Western Reserve University. The award includes a $25,000 cash prize that is intended to support the awardee’s further research.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.